Search company, investor...

NB Therapeutics

nitricbio.com

Founded Year

2006

Stage

Debt - III | Dead

Total Raised

$11.45M

Last Raised

$1.02M

About NB Therapeutics

NB Therapeutics, formerly Theranox, is a biopharmaceutical and medical device company focused on developing and commercializing pharmacologic therapies to address opportunities in the dermatology and podiatry markets with unmet needs. NB Therapeutics has two technology platforms: iontophoresis and nitric oxide gas. Through these two technology platforms, NB Therapeutics seeks to address the inherent challenges of drug delivery for diseases of the skin and nails. The company has advanced compounds from both of its technology platforms to human clinical trials. Nitric Bio's lead compound in development is a patented, ionized formulation of terbinafine which is delivered to the nail and nail bed through iontophoresis for the treatment of onychomycosis.

Headquarters Location

2 Canals End Road

Bristol, Pennsylvania, 19007,

United States

215-788-6200

Missing: NB Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NB Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

NB Therapeutics Patents

NB Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/20/2013

Suites, Windows commands, Windows administration, Command shells, Interpreters (computing)

Application

Application Date

6/20/2013

Grant Date

Title

Related Topics

Suites, Windows commands, Windows administration, Command shells, Interpreters (computing)

Status

Application

Latest NB Therapeutics News

NB Therapeutics raising $1 million to fund nail fungus therapy

Nov 29, 2011

Share / Nov 29, 2011 at 5:31 PM Nitric BioTheraputics , a biopharmaceutical and medical device company, is raising $1 million to fund clinical trials of its drug-delivery therapy for onychomycosis, a type of nail fungus, according to the CEO of the company, Frank McCaney. The company filed a Form D filing with the U.S. Securities and Exchange Commission dated Nov. 29. The Bristol, Pennsylvania company is conducting phase 2 clinical trials using iontophoresis as a drug-delivery platform to treat onychomycosis —  one of the most common types of toenail and fingernail fungal infections, causing half of all nail disorders — and nongenital warts. Iontophoresis involves using electric currents to improve drug delivery through the skin and nails, a method the company says improves drug delivery since it can facilitate delivery of high concentrations of a medication in a single dose and is pain free for patients. Advertisement NuPathe also uses iontophoresis technology for its migraine patch . The second therapy is nitric oxide to treat fungal infections between digits, referred  to as tinea pedis, and skin and soft tissue infections. A regulatory molecule, varied concentrations of nitric oxide may have different effects, according to the company’s website. A significant challenge to obtaining the desired effect of nitric oxide is getting the right concentrations of the drug for a specific exposure. Among the company’s backers are Radnor, Pennsylvania-based New Spring Ventures , Quaker BioVenture s in Philadelphia and Cardinal Health spinoff CareFusion in Dublin, Ohio. Last year, NB Therapeutics raised $1.7 million of an ongoing funding round that was projected to reach $20 million . It had raised $1.7 million in 2009. Topics

NB Therapeutics Frequently Asked Questions (FAQ)

  • When was NB Therapeutics founded?

    NB Therapeutics was founded in 2006.

  • Where is NB Therapeutics's headquarters?

    NB Therapeutics's headquarters is located at 2 Canals End Road, Bristol.

  • What is NB Therapeutics's latest funding round?

    NB Therapeutics's latest funding round is Debt - III.

  • How much did NB Therapeutics raise?

    NB Therapeutics raised a total of $11.45M.

  • Who are the investors of NB Therapeutics?

    Investors of NB Therapeutics include NewSpring Capital, Quaker BioVentures, BioStar Capital, Commerce Health Ventures, VIASYS Healthcare and 3 more.

  • Who are NB Therapeutics's competitors?

    Competitors of NB Therapeutics include CVRx, Adhezion Biomedical, TxCell, Intercept Pharmaceuticals, NeurAxon and 12 more.

Compare NB Therapeutics to Competitors

I
ISW Group

ISW Group is a pharmaceutical company that researches and aims to develop FDA approved topical products for the management and treatment of acute and chronic inflammatory skin conditions. ISW Group's research program focuses on acute and chronic dermatologic irritation and inflammation associated with dermatitis, Pseudofolliculitis barbae, burn care and wound healing.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

A
Asterion

Asterion is a manufacturer of analog semiconductors.

V
Valderm Aps

Valderm ApS is focused on the development of the second generation anthracycline valrubicin for once daily topical treatment of hyperproliferative skin diseases e.g. psoriasis.

TxCell Logo
TxCell

TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with hight unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis. The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link). The company's lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments.

T
Type IV Technologies

Type IV Technologies, L.L.C. ("Type IV"), is a company formed in 2002 to develop a new therapy that will change the current standard of care for people with warts. This new therapy, immunotherapy for Human Papillomavirus (HPV) infections, involves using FDA-approved skin test antigens both by themselves and in combination to induce an immunologic response that rids the body of warts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.